Related Centers

    • This Center has a core grant to develop a new biomarker for CFTR and is currently the central reading site for this CFTR biomarker.
    • Dr. Steven Rowe is the international PI of the VX-809 study (targeting DF508 CFTR, the most common cause of CF)
    • Dr. Steven Rowe is the Co-PI of the international study of PTC124 (targeting premature stop mutations in CFTR).  This agent grew out of observations piloted by Dr. David Bedwell of UAB Microbiology.
    • UAB was the top enrolling site in the recently completed Phase II study of VX-770 (targeting gating effects in CFTR).